Approximately 30-50% of patients with NKX2-1 gene mutations have the classic brain-lung-thyroid triad (41), which manifests as neurological symptoms, such as chorea and dystonia in early infancy, along with abnormal thyroid function and respiratory diseases, such as neonatal respiratory distress syndrome and interstitial lung disease. This evidence concerns the gene NKX2-1 and choreatic disease.